⌕
Scinai Immunotherapeutics · SCNI · Nasdaq
Tenet 21 · Weak
Compare
$1.55+323.14%At closeTenet 21 · Weak
$1.55+1.19 (+323.14%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Scinai Immunotherapeutics (SCNI) Key Ratios

Valuation, quality, health and growth. Every ratio ranked against its sector peers — the number we score — with its own ten-year record shown beside it for context.

Sources Company filings and market prices Filings and pricesRatios computed How we compute thisNot investment advice
—
VALUE
No data
no inputs scored
9
QUALITY
Weak
below-peer returns
32
HEALTH
Fragile
leverage needs watching
—
GROWTH
Not scored
no measurable growth rate; left out of the composite

A weak business at a no data price: quality 9, health 32, each a percentile within Healthcare.

Values are the trailing twelve months where a company files quarterly statements and the figure passes our check against the filings, with balance-sheet ratios from the most recent quarter; otherwise, or where a sector's figure is still under review, the latest fiscal year. Piotroski and the five-year growth rates are fiscal years. Each row names its period.track = where peers land, worse → better (direction-adjusted: right always means better)▏sector median● you are here▲ where today's value sits in the company's own ten fiscal years (context, not scored)hover any metric for its formula
no inputs scored
Earnings yield (EBIT/EV)EBIT (operating income) for the latest fiscal year ÷ enterprise value on the current market cap (Greenblatt). The vendor's own earnings yield is net income to common ÷ market cap, a different figure.—Withheld: the share basis behind this valuation is not verified.
P/E—Withheld: the share basis behind this valuation is not verified.
P/B—Withheld: the share basis behind this valuation is not verified.
P/FCF—Withheld: the share basis behind this valuation is not verified.
EV / EBITDA—Withheld: the share basis behind this valuation is not verified.
32nd pctileleverage needs watching
Current ratio1.3011th pctileMost recent quarter, Dec 31, 2025
Quick ratio(Cash, short-term investments and receivables) ÷ current liabilities, as the data vendor builds it. Its receivables include non-trade receivables, which Tenet's balance sheet shows inside other current assets.1.0918th pctileMost recent quarter, Dec 31, 2025
Net debt / EBITDA(Total debt − cash) ÷ EBITDA—Not meaningful: EBITDA is zero or negative.
Interest coverage—Not meaningful: operating income is zero or negative.
Debt / equity0.0467th pctileown record too shortMost recent quarter, Dec 31, 2025
9th pctilebelow-peer returns
ROIC−63%15th pctileown record too shortTTM through Dec 31, 2025 (fiscal 2025)
ROE−92%13th pctileown record too shortTTM through Dec 31, 2025 (fiscal 2025)
Gross margin−202.3%1st pctileown record too shortTTM through Dec 31, 2025 (fiscal 2025)
Net margin—Not reported in the company's filings for this period.
Income quality (CFO/NI)—Not meaningful: the company made a loss.
Piotroski F2 / 916th pctileown record too shortFiscal 2025 (Dec 31, 2025)
Altman Z−16.81st pctileTTM through Dec 31, 2025 (fiscal 2025)
no measurable growth rate; left out of the composite
Revenue CAGRThe yearly rate that compounds the earliest fiscal year's revenue into the latest one, over the true number of fiscal years between them (up to five). When the earliest year's revenue is zero or negative, the rate starts from the first later year with at least $10M of revenue, provided at least three years remain.—This growth figure starts in a period outside the history your plan includes.
EPS CAGR—This growth figure starts in a period outside the history your plan includes.
FCF margin—Withheld: this figure is outside the range we accept for its kind.
the receipts behind the numbers above
Greenblatt earnings yield—EBIT ÷ EV The vendor's "earningsYield" is NI ÷ market cap, which is not Greenblatt's formula.
ROIC−63%NOPAT ÷ invested capital The vendor's simple ROIC, not its tiny-base roic tag; withheld when a negative EBIT flips its sign.
Interest coverage— Guarded, not faked: we have no interest-expense figure on file for this company, so it's excluded from the ranking instead of rendered as garbage.
Percentiles computed nightly against 486 Healthcare peers from our ingested fundamentals DB · raw statements for corrected metrics. Direction-adjusted: for "lower is better" ratios (P/E, D/E…) the percentile is flipped so right always means better. The percentile is the stock's rank among sector peers, the number that is scored. The triangle marks where the current value (the trailing twelve months or the latest fiscal year, as its row names) sits in the company's own ten fiscal-year record, shown for context and never blended into the score. Computed Nov 20, 2026 · Not investment advice.

What is Scinai Immunotherapeutics' Piotroski F-Score?

Scinai Immunotherapeutics' Piotroski F-Score is 2 of 9 for fiscal 2025.

What is Scinai Immunotherapeutics' Altman Z-Score?

Scinai Immunotherapeutics' Altman Z-Score is −16.8, TTM through Dec 31, 2025 (fiscal 2025).

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.